When starting etanercept for RA in a patient with hypertension and AF on warfarin, what is the most important consideration?

• A. Infection risk is increased; assess for active infections before starting
• B. Etanercept is contraindicated in all patients with prior infections
• C. Warfarin must be stopped during etanercept therapy
• D. No special infection considerations are needed

Answer: (A)

Infection risk is the key issue when starting etanercept. Etanercept is a TNF inhibitor that dampens parts of the immune system, so it increases the risk of infections, including serious ones and reactivation of latent tuberculosis. Before initiating therapy, the priority is to assess for any active infection and screen for latent infections (such as TB and hepatitis B/C) and update vaccines as needed. If an active infection is present, treat or delay starting etanercept until it’s resolved.

Warfarin use does not require stopping the anticoagulant simply because a TNF inhibitor is being started; anticoagulation should be managed as clinically indicated, but it isn’t the primary concern when weighing infection risk.

So the most important consideration is ensuring no active infection and identifying latent infections before starting therapy.